Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038232 · ClinicalTrials.gov registry record
Measuring Distress Tolerance With Functional MRI
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 99
- Enrollment target
NCT01038232: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01038232 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038232 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
Background: \- People who are in treatment for substance abuse often feel distress during the withdrawal period and afterward. Some individuals feel distress more acutely than others, and this distress has been linked to poor treatment outcomes and increased risk of relapse in smokers, alcoholics, and cocaine- and heroin-dependent individuals. More research is needed on the effects of distress on the brain, particularly in individuals who are seeking treatment for substance abuse. Researchers are interested in using functional magnetic resonance imaging (fMRI) scanning to study distress tolerance in both substance users seeking treatment and healthy non-drug-using volunteers. Objectives: \- To use functional magnetic resonance imaging to study the effectiveness of a distress tolerance assessment. Eligibility: \- Individuals between 18 and 50 years of age who are either cocaine dependent or healthy non-drug-using volunteers. Design: * This study involves an initial screening visit and a scanning visit, with four followup visits. * Participants will be screened with a medical history and physical examination, as well as blood samples and questionnaires about mood and past and current drug use. * Participants will have a structural MRI scan of the brain to provide a baseline reading for comparison. Participants will then have an fMRI scanning session, which will include both the distress tolerance assessment and relevant control tasks. Heart rate, blood pressure, and other physical reactions will be monitored throughout the scan. Participants will also provide blood and saliva samples to measure stress hormone levels. * Participants will be eligible to have followup assessments with fMRI scanning 1, 3, 6, and 12 months after the scanning visit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2009-12-04 |
| Est. Completion | 2015-03-24 |
What the finished NCT01038232 record still lists
NCT01038232 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01038232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01038232 about?
NCT01038232 is a clinical study titled "Measuring Distress Tolerance With Functional MRI". Background: \- People who are in treatment for substance abuse often feel distress during the withdrawal period and afterward. Some individuals feel distress more acutely than others, and this distress has been linked to poor treatment outcomes and increased risk of relapse in smokers, alcoholics, ...
What is the current status of trial NCT01038232?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2009-12-04. Estimated completion is 2015-03-24.
Who is sponsoring clinical trial NCT01038232?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI